Latest news with #BOT
Yahoo
4 days ago
- Business
- Yahoo
Agenus Inc. (AGEN) Surges After Zydus Agreement, Analysts Upbeat on Stock
Agenus Inc. (NASDAQ:AGEN) is among the 10 Most Undervalued Stocks to Buy for Under $5. Despite a 39% surge over the past month, it is still a bargain stock, considering its low forward price-earnings ratio. A research doctor, looking intently at their microscope as they try to decipher the mysteries of immuno-oncology. The company's shares have soared on the back of notable recent developments. On June 3, Agenus Inc. (NASDAQ:AGEN) announced that it had signed agreements worth $141 million with Zydus Lifesciences Ltd. and its subsidiaries to accelerate the clinical development of botensilimab and balstilimab (BOT/BAL). Under the agreement, Agenus Inc. (NASDAQ:AGEN) will receive $75 million upfront for the transfer of two manufacturing assets in California. The company will also get an additional $50 million in contingent payments triggered by BOT/BAL production orders. Moreover, it will grant Zydus a license to develop and commercialize BOT and BAL in India and Sri Lanka, with a 5% royalty on net sales to be paid to Agenus. Following the development, analysts at H.C. Wainwright upgraded Agenus Inc. (NASDAQ:AGEN)'s rating from Neutral to Buy, whereas Baird lifted the stock's price target to $6 from $4, while maintaining a Neutral rating for its shares. Investor sentiment in Agenus Inc. (NASDAQ:AGEN) has also been strengthened by recent quarter results, in which the company managed to significantly lower its loss per share to $1.03 from $3.04 in the prior year. While we acknowledge the potential of AGEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Agenus Inc. (AGEN) Surges After Zydus Agreement, Analysts Upbeat on Stock
Agenus Inc. (NASDAQ:AGEN) is among the 10 Most Undervalued Stocks to Buy for Under $5. Despite a 39% surge over the past month, it is still a bargain stock, considering its low forward price-earnings ratio. A research doctor, looking intently at their microscope as they try to decipher the mysteries of immuno-oncology. The company's shares have soared on the back of notable recent developments. On June 3, Agenus Inc. (NASDAQ:AGEN) announced that it had signed agreements worth $141 million with Zydus Lifesciences Ltd. and its subsidiaries to accelerate the clinical development of botensilimab and balstilimab (BOT/BAL). Under the agreement, Agenus Inc. (NASDAQ:AGEN) will receive $75 million upfront for the transfer of two manufacturing assets in California. The company will also get an additional $50 million in contingent payments triggered by BOT/BAL production orders. Moreover, it will grant Zydus a license to develop and commercialize BOT and BAL in India and Sri Lanka, with a 5% royalty on net sales to be paid to Agenus. Following the development, analysts at H.C. Wainwright upgraded Agenus Inc. (NASDAQ:AGEN)'s rating from Neutral to Buy, whereas Baird lifted the stock's price target to $6 from $4, while maintaining a Neutral rating for its shares. Investor sentiment in Agenus Inc. (NASDAQ:AGEN) has also been strengthened by recent quarter results, in which the company managed to significantly lower its loss per share to $1.03 from $3.04 in the prior year. While we acknowledge the potential of AGEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Time of India
11-06-2025
- Time of India
Two dead, four injured as gate of Sambhajinagar's Siddharth Garden collapses due to heavy winds
Chhatrapati Sambhajinagar: Two women died and four others sustained injuries when the main entrance gate of the civic body-run Siddharth Garden collapsed because of strong winds at 6.30pm on Wednesday. The deceased have been identified as Swati Khairnath, a 37-year-old from Dhamangao, and Rekha Gaikwad, a 60-year-old resident of the TV Centre area. Among those hurt, Shaikh Akhil (27) suffered severe injuries and was taken to the Government Medical College and Hospital (GMCH). The entrance gate, constructed with cement blocks in a dome-like design, was a recent addition built under a build-operate-transfer (BOT) agreement. It collapsed onto the victims during strong winds. Witnesses reported that the public garden was crowded, and some visitors sought shelter from rain under the entrance gate when the incident occurred. The falling debris struck the victims' heads with great force, causing lethal head injuries. Hospital authorities at the GMCH confirmed that both women were deceased upon arrival. Chhatrapati Sambhajinagar municipal commissioner G Sreekanth, upon visiting the incident site, announced that legal action would be taken against the private company responsible for constructing the entrance gate and other structures at the public garden under the BOT contract. "The private firm was expected to check structural strength and carry out periodic maintenance, but that did not happen. The public garden will be closed for the next seven days until the structural audit of the public garden is completed," he said. Sreekanth added that district guardian minister Sanjay Shirsat had declared Rs 5 lakh ex gratia for the families of both deceased women. Chhatrapati Sambhajinagar experienced thunderstorms with strong winds and varying intensities of rainfall on Wednesday evening. Fire brigade officials reported six instances of fallen trees across different locations, with one incident resulting in minor injuries to a girl in the Bhagat Singh area. Numerous areas of the city experienced power outages due to adverse weather conditions, with electricity restoration delayed until late at night in several regions.
CNA
05-06-2025
- Business
- CNA
Four candidates confirm applications for Bank of Thailand Governor
BANGKOK : A university dean, a board member at the state planning agency and the head of a state bank are among the seven candidates to Thailand's next central bank governor, with the selection committee to prepare a shortlist over the next month. By Thursday, four people had publicly confirmed their interest in the role after the finance ministry said on Wednesday it had received seven applications. The selection committee plans to shortlist at least two candidates to succeed Sethaput Suthiwartnarueput by July 2, with the finance minister to bring the name of his preferred candidate to cabinet. The final appointment will require cabinet and royal approval. "The country is facing serious problems... I want to propose how monetary policy can help," Somprawin Manprasert, a board member at the state planning agency and former chief economist at Siam Commercial Bank, told Reuters when confirming his bid. "Even if I'm not chosen, whoever is can use those proposals," said the 50-year-old, who holds a doctorate in economics from the University of Maryland. Anusorn Tamajai, the dean of economics at the University of the Thai Chamber of Commerce, also confirmed his candidacy to Reuters. The 59-year-old has been a BOT board member and also served on the Finance Ministry's debt management committee. Other candidates to confirm to Thai media that they had applied for the role are Vitai Ratanakorn, the 54-year-old president of the state-owned Government Savings Bank who previously led Thailand's $34 billion Government Pension Fund, and Kobsak Pootrakool, chairman of the Federation of Thai Capital Market Organizations. Kobsak, 56, served as minister attached to the Prime Minister's Office from 2017 to 2019, and has worked in the BOT's Monetary Policy Department. Local media have reported three other applicants, including two women, who have not publicly confirmed their interest. A current BOT deputy governor, Roong Mallikamas, was reported to have applied. The 56-year-old has held senior roles in financial markets and monetary policy in her two-decade career at the central bank. She declined to comment when contacted by Reuters. Another reported applicant is former IMF economist and finance ministry official, Sutapa Amornvivat, who is the CEO of fintech lender Abacus Digital. The 50-year-old is a cousin of Deputy Finance Minister Julapun Amornvivat. She declined to comment when contacted by Reuters. Thai media also reported businessman and politician Vikran Supamongkol had applied for the role. Reuters could not immediately reach him for comment on whether he was a candidate.
Mint
04-06-2025
- Business
- Mint
Zydus to Enter Global Biologics CDMO Business Plans
New Jersey, United States & Ahmedabad, Gujarat, India – Business Wire India Zydus Lifesciences Ltd. (including its subsidiaries/affiliates, hereafter referred to as 'Zydus) today announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.'s (Nasdaq: AGEN) U.S.-based biologics CMC facilities. This acquisition marks Zydus' strategic investment in U.S.-based manufacturing for biologics thereby adding a sustainable growth driver for the group. Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Under the terms of the agreement, Zydus will acquire two state-of-the-art biologics manufacturing facilities from Agenus in Emeryville and Berkeley, California (US) for an upfront consideration of US$75 million and contingent payment of US$50 million to be paid over three years subject to achievement of certain revenue milestone. This acquisition provides Zydus immediate access to advanced biologics manufacturing capabilities and establishes a key presence in California, a leading global biotechnology hub. This strategic move enables Zydus to leverage supply chain dynamics and a favourable geopolitical environment to expand its reach in the U.S. and globally. With this acquisition Zydus will now become a one stop solution provider across the entire development spectrum of biologics, right from pre-clinical to toxicology studies, clinical development and now CDMO business will operate as an independent entity and will house the acquired manufacturing capabilities. The facilities come with an experienced professional team with strong capabilities and requisite industry expertise to deliver high-quality biologics development and manufacturing services to global biotech and pharmaceutical companies. As a part of transaction Zydus will become an exclusive contract manufacturer for Agenus and will provide manufacturing services for clinical and commercial supply of two identified Phase-3 ready immuno-oncology products, Botensilimab (BOT) and Balstilimab (BAL). Zydus will also have first right of negotiation to manufacture any of the future pipeline products developed by Agenus. Zydus intends to further expand the team and help create new jobs in the region and contribute to the local on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd. said, "The acquisition will give Zydus a strategic foothold in the U.S. for biologics manufacturing in the global hub for biotech innovation, California. It will enhance our ability to partner with innovation-centric entities, advancing new products and prioritizing patient-centric solutions. This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry." The global biologics CDMO market is experiencing significant growth, driven by the increasing complexity of therapies, the rise of biologics in clinical pipelines, and a growing number of emerging biotech companies lacking internal manufacturing capabilities. According to the Global Biologics CDMO Market Size is expected to be worth around US$ 84.9 Billion by 2034, growing at a CAGR of 15.7% between 2025 to 2034. As demand surges for reliable, agile, and scalable partners, Zydus' entry into this space positions it to tap into significant long-term growth opportunities and support innovation across the global biopharmaceutical landscape. About Zydus Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars. For more details visit: About Agenus Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Leveraging proprietary scientific platforms, the company's pipeline includes multiple checkpoint antibody candidates, vaccines, and cell therapies. Headquartered in Lexington, MA, Agenus operates globally, driving innovations to bring better cancer treatments to patients. For more details visit: Forward-Looking Statements: This press release contains forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, but are not limited to, the successful integration of the acquired business, market conditions, and other factors. Sujatha Rajesh (Media Relations), Zydus Lifesciences Limited, +91-9974051180 Arvind Bothra (Investor Relations), Zydus Lifesciences Limited, +91-7045656895
